EML4 and non-small cell lung carcinoma: From 1697 DEGs that showed anti-similarity (or inverse correlation) between these two datasets (Supplementary Fig. 1e, f), we identified EMT as a clinically significant hallmark signature; the EMT signature was enhanced in patients with NSCLC bearing EML4-ALK, whereas it was decreased by crizotinib (Table 1 and Supplementary Fig. 2).